Mioticol

Mioticol Uses, Dosage, Side Effects, Food Interaction and all others data.

Mioticol, also known as carbachol, is a muscarinic agonist discovered in 1932. Mioticol was initially used as a treatment for migraines, induction of diuresis, and other parasympathetic effects.

Mioticol was granted FDA approval on 28 September 1972.

Mioticol is a parasympathomimetic that acts as an agonist of muscarinic and nicotinic receptors. It is more resistant to hydrolysis by acetylcholinesterase than other choline esters leading to a longer duration of action, with significant effects 24 hours after administration. Data regarding the therapeutic index of carbamoylcholine is not readily available. Patients should be counselled regarding the risk of administering the drug to patients with acute cardiac failure, bronchial asthma, peptic ulcer, hyperthyroidism, gastrointestinal spasm, urinary tract obstruction, or Parkinson's disease.

Trade Name Mioticol
Generic Carbamoylcholine
Carbamoylcholine Other Names Carbacholine, carbacol, Carbamylcholine, Choline carbamate, Carbachol
Type
Formula C6H15N2O2
Weight Average: 147.1955
Monoisotopic: 147.113352734
Protein binding

Data regarding protein binding of carbamoylcholine is not readily available.

Groups Approved
Therapeutic Class
Manufacturer
Available Country
Last Updated: September 19, 2023 at 7:00 am
Mioticol
Mioticol

Uses

Carbachol is a direct acting miotic agent administered ophthalmically to decrease intraocular pressure after cataract surgery, and to induce miosis during surgery.

Mioticol is indicated to induce miosis for surgery and to reduce intraocular pressure elevations in the first 24 hours after cataract surgery.

Mioticol is also used to associated treatment for these conditions: Increased Intra Ocular Pressure (IOP), Open Angle Glaucoma (OAG), Acute Angle closure glaucoma

How Mioticol works

Mioticol is a parasympathomimetic that acts as an agonist of muscarinic and nicotinic receptors. Intraocular administration leads to miosis and decreases intraocular pressure via increased aqueous humour outflow.

Toxicity

Patients experiencing an overdose of carbamoylcholine may experience nausea, sweating, hypotension, hypersalivation, bronchorrhea, miosis, and dyspnea. Patients should be treated with symptomatic and supportive treatment. Treatment may include atropine, furosemide, epinephrine, and/or dopamine. Some patients may require intubation.

The oral LD50 in mice is 15 mg/kg and in rats is 40 mg/kg.

Food Interaction

No interactions found.

Volume of Distribution

Data regarding the volume of distribution of carbamoylcholine is not readily available.

Elimination Route

Choline esters in general are hydrophilic and therefore poorly absorbed through the gastrointestinal tract and are unlikely to cross the blood brain barrier. Data regarding the absorption of carbamoylcholine are not readily available.

Half Life

Data regarding the half life of carbamoylcholine is not readily available.

Clearance

Data regarding the clearance of carbamoylcholine is not readily available.

Elimination Route

Data regarding the route of elimination of carbamoylcholine is not readily available.

Innovators Monograph

You find simplified version here Mioticol

*** Taking medicines without doctor's advice can cause long-term problems.
Share